Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

RxSight (RXST) EBITDA (2020 - 2026)

RxSight filings provide 6 years of EBITDA readings, the most recent being -$9.2 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 45.56% to -$9.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$39.1 million, a 43.15% decrease, with the full-year FY2025 number at -$39.1 million, down 43.15% from a year prior.
  • EBITDA hit -$9.2 million in Q4 2025 for RxSight, up from -$9.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$5.7 million in Q3 2024 to a low of -$17.7 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$12.2 million (2023), compared with a mean of -$11.5 million.
  • Biggest five-year swings in EBITDA: tumbled 159.87% in 2021 and later surged 55.7% in 2024.
  • RxSight's EBITDA stood at -$15.7 million in 2021, then rose by 1.12% to -$15.6 million in 2022, then soared by 41.4% to -$9.1 million in 2023, then soared by 31.01% to -$6.3 million in 2024, then plummeted by 45.56% to -$9.2 million in 2025.
  • The last three reported values for EBITDA were -$9.2 million (Q4 2025), -$9.6 million (Q3 2025), and -$11.9 million (Q2 2025) per Business Quant data.